AUS
NZ
UK
CA
USA
IND
Highlights:
- Revenue of $1.1M in Q3 2025 shows strong growth, up 34% from Q2 and 175% YoY.
- CE Mark approval in Europe and Market Authorization in Australia expand LungFit PH’s global reach.
- Six new U.S. hospital implementations and strategic partnerships in the Middle East.
Beyond Air (NASDAQ:XAIR), a leading innovator in medical devices, has reported strong financial results for its fiscal Q3 2025, demonstrating continued momentum in both revenue growth and global expansion. The company achieved revenues of $1.1 million for the quarter, marking a 34% increase from the previous quarter and an impressive 175% year-over-year growth. This performance underscores the company’s successful efforts to scale its operations and advance its market presence, particularly for its flagship product, LungFit PH, a nitric oxide delivery system for pulmonary hypertension.
A key milestone for Beyond Air during the quarter was the receipt of the CE Mark for LungFit PH in Europe, along with Market Authorization in Australia. These approvals significantly expand the company’s global reach and provide a pathway for broader market adoption of its innovative technology. LungFit PH is designed to improve the treatment of pulmonary hypertension by offering a non-invasive solution to deliver nitric oxide, a critical therapy for managing the condition.
Beyond Air’s global footprint continued to expand in Q3, with the company initiating six new hospital implementations in the United States. In addition to this, the company also formed strategic partnerships with two distributors in the Middle East, further extending its market presence. These developments are expected to contribute to continued growth in the coming quarters.
The company also reported a $1 million milestone payment triggered by its partnership with Getz Healthcare, which will further support its operations and product expansion efforts. Despite the strong growth in revenue, Beyond Air’s operating expenses showed significant improvement, with research and development (R&D) expenses decreasing from $6.8 million in Q3 2024 to $3.0 million in Q3 2025. Selling, general, and administrative (SG&A) expenses also declined to $7.7 million from $9.8 million in the previous year, reflecting the company's focus on cost management.
However, the company did experience some challenges. The cost of revenue for the quarter was $1.3 million, which exceeded its revenue of $1.1 million, resulting in a gross loss. Additionally, the company reported a quarterly cash burn of $7.6 million. These figures highlight the ongoing costs associated with scaling operations and investing in product development, as Beyond Air continues to build out its infrastructure to support its growth.
Beyond Air ended the quarter with cash and equivalents of $10.9 million, along with total debt of $11.8 million. The company expects its cash runway to extend well into 2026, providing sufficient resources to continue its expansion efforts and investment in R&D.
Looking forward, Beyond Air is focused on expanding its market presence, continuing to build out its hospital implementations, and driving further adoption of its LungFit PH product globally. The company remains optimistic about its growth trajectory, particularly with the recent approvals in Europe and Australia, and with new partnerships paving the way for further expansion in key markets.
